These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 26298771)

  • 1. Association between TERT promoter polymorphisms and acute myeloid leukemia risk and prognosis.
    Mosrati MA; Willander K; Falk IJ; Hermanson M; Höglund M; Stockelberg D; Wei Y; Lotfi K; Söderkvist P
    Oncotarget; 2015 Sep; 6(28):25109-20. PubMed ID: 26298771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic quality of activating TERT promoter mutations in glioblastoma: interaction with the rs2853669 polymorphism and patient age at diagnosis.
    Spiegl-Kreinecker S; Lötsch D; Ghanim B; Pirker C; Mohr T; Laaber M; Weis S; Olschowski A; Webersinke G; Pichler J; Berger W
    Neuro Oncol; 2015 Sep; 17(9):1231-40. PubMed ID: 25681309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic landscape of the TERT promoter: a potential biomarker for high risk AML/MDS.
    Zhao X; Tian X; Kajigaya S; Cantilena CR; Strickland S; Savani BN; Mohan S; Feng X; Keyvanfar K; Dunavin N; Townsley DM; Dumitriu B; Battiwalla M; Rezvani K; Young NS; Barrett AJ; Ito S
    Br J Haematol; 2016 Nov; 175(3):427-439. PubMed ID: 27433923
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The association between the TERT rs2736100 AC genotype and reduced risk of upper tract urothelial carcinomas in a Han Chinese population.
    Yuan X; Meng Y; Li P; Ge N; Kong F; Yang L; Björkholm M; Zhao S; Xu D
    Oncotarget; 2016 May; 7(22):31972-9. PubMed ID: 26934125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TERT promoter mutations and rs2853669 polymorphism: prognostic impact and interactions with common alterations in glioblastomas.
    Nencha U; Rahimian A; Giry M; Sechi A; Mokhtari K; Polivka M; Schmitt Y; Di Stefano AL; Alentorn A; Labussière M; Sanson M
    J Neurooncol; 2016 Feb; 126(3):441-6. PubMed ID: 26608520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutational spectrum and risk stratification of intermediate-risk acute myeloid leukemia patients based on next-generation sequencing.
    Wang B; Liu Y; Hou G; Wang L; Lv N; Xu Y; Xu Y; Wang X; Xuan Z; Jing Y; Li H; Jin X; Deng A; Wang L; Gao X; Dou L; Liang J; Chen C; Li Y; Yu L
    Oncotarget; 2016 May; 7(22):32065-78. PubMed ID: 27062340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The lincRNA HOTAIRM1, located in the HOXA genomic region, is expressed in acute myeloid leukemia, impacts prognosis in patients in the intermediate-risk cytogenetic category, and is associated with a distinctive microRNA signature.
    Díaz-Beyá M; Brunet S; Nomdedéu J; Pratcorona M; Cordeiro A; Gallardo D; Escoda L; Tormo M; Heras I; Ribera JM; Duarte R; de Llano MP; Bargay J; Sampol A; Nomdedeu M; Risueño RM; Hoyos M; Sierra J; Monzo M; Navarro A; Esteve J;
    Oncotarget; 2015 Oct; 6(31):31613-27. PubMed ID: 26436590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prognostic impact of TERT promoter mutations in glioblastomas is modified by the rs2853669 single nucleotide polymorphism.
    Batista R; Cruvinel-Carloni A; Vinagre J; Peixoto J; Catarino TA; Campanella NC; Menezes W; Becker AP; de Almeida GC; Matsushita MM; Clara C; Neder L; Viana-Pereira M; Honavar M; Castro L; Lopes JM; Carvalho B; Vaz RM; Máximo V; Soares P; Sobrinho-Simões M; Reis RM; Lima J
    Int J Cancer; 2016 Jul; 139(2):414-23. PubMed ID: 26914704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TERT promoter mutations in gliomas, genetic associations and clinico-pathological correlations.
    Labussière M; Di Stefano AL; Gleize V; Boisselier B; Giry M; Mangesius S; Bruno A; Paterra R; Marie Y; Rahimian A; Finocchiaro G; Houlston RS; Hoang-Xuan K; Idbaih A; Delattre JY; Mokhtari K; Sanson M
    Br J Cancer; 2014 Nov; 111(10):2024-32. PubMed ID: 25314060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The TERT promoter mutation incidence is modified by germline TERT rs2736098 and rs2736100 polymorphisms in hepatocellular carcinoma.
    Yuan X; Cheng G; Yu J; Zheng S; Sun C; Sun Q; Li K; Lin Z; Liu T; Li P; Xu Y; Kong F; Bjorkholm M; Xu D
    Oncotarget; 2017 Apr; 8(14):23120-23129. PubMed ID: 28416747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor.
    Wagner K; Damm F; Göhring G; Görlich K; Heuser M; Schäfer I; Ottmann O; Lübbert M; Heit W; Kanz L; Schlimok G; Raghavachar AA; Fiedler W; Kirchner HH; Brugger W; Zucknick M; Schlegelberger B; Heil G; Ganser A; Krauter J
    J Clin Oncol; 2010 May; 28(14):2356-64. PubMed ID: 20368538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical characteristics and prognostic study of adult acute myeloid leukemia patients with
    Lin Y; Wang Y; Zheng Y; Wang Z; Wang Y; Wang S
    Hematology; 2020 Dec; 25(1):446-456. PubMed ID: 33250015
    [No Abstract]   [Full Text] [Related]  

  • 13. TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism.
    Rachakonda PS; Hosen I; de Verdier PJ; Fallah M; Heidenreich B; Ryk C; Wiklund NP; Steineck G; Schadendorf D; Hemminki K; Kumar R
    Proc Natl Acad Sci U S A; 2013 Oct; 110(43):17426-31. PubMed ID: 24101484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TERT rs2853669 as a predictor for overall survival in patients with acute myeloid leukaemia.
    Tripon F; Bănescu C; Trifa AP; Crauciuc AG; Moldovan VG; Boglis A; Benedek I; Demian S; Duicu C; Iancu M
    Arch Med Sci; 2022; 18(1):103-111. PubMed ID: 35154531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TERT genetic variability and telomere length as factors affecting survival and risk in acute myeloid leukaemia.
    Dratwa M; Wysoczańska B; Butrym A; Łacina P; Mazur G; Bogunia-Kubik K
    Sci Rep; 2021 Dec; 11(1):23301. PubMed ID: 34857839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Co-occurrence of Myeloproliferative Neoplasms and Solid Tumors Is Attributed to a Synergism Between Cytoreductive Therapy and the Common TERT Polymorphism rs2736100.
    Krahling T; Balassa K; Kiss KP; Bors A; Batai A; Halm G; Egyed M; Fekete S; Remenyi P; Masszi T; Tordai A; Andrikovics H
    Cancer Epidemiol Biomarkers Prev; 2016 Jan; 25(1):98-104. PubMed ID: 26487696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TERT promoter mutations in soft tissue sarcomas.
    Campanella NC; Penna V; Abrahão-Machado LF; Cruvinel-Carloni A; Ribeiro G; Soares P; Scapulatempo-Neto C; Reis RM
    Int J Biol Markers; 2016 Feb; 31(1):e62-7. PubMed ID: 26391479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Telomerase reverse transcriptase (TERT) A1062T mutation as a prognostic factor in Egyptian patients with acute myeloid leukemia (AML).
    Aref S; El-Ghonemy MS; Abouzeid TE; El-Sabbagh AM; El-Baiomy MA
    Med Oncol; 2014 Sep; 31(9):158. PubMed ID: 25108601
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 5-Hydroxymethylcytosine correlates with epigenetic regulatory mutations, but may not have prognostic value in predicting survival in normal karyotype acute myeloid leukemia.
    Ahn JS; Kim HJ; Kim YK; Lee SS; Ahn SY; Jung SH; Yang DH; Lee JJ; Park HJ; Choi SH; Jung CW; Jang JH; Kim HJ; Moon JH; Sohn SK; Won JH; Kim SH; Michael S; Minden MD; Kim DD
    Oncotarget; 2017 Jan; 8(5):8305-8314. PubMed ID: 28039446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TERT promoter mutations and polymorphisms as prognostic factors in primary glioblastoma.
    Mosrati MA; Malmström A; Lysiak M; Krysztofiak A; Hallbeck M; Milos P; Hallbeck AL; Bratthäll C; Strandéus M; Stenmark-Askmalm M; Söderkvist P
    Oncotarget; 2015 Jun; 6(18):16663-73. PubMed ID: 26143636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.